These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38719255)

  • 1. Immune checkpoint inhibitor associated diarrhoea.
    Al-Hussainy A; Adams J; Simmons J; Kennedy J
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy.
    Prasanna T; McNeil CM; Nielsen T; Parkin D
    Immunotherapy; 2018 Mar; 10(3):171-175. PubMed ID: 29370723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diarrhoea during checkpoint blockade, not always colitis.
    Koldenhof JJ; Suijkerbuijk KPM
    Eur J Cancer; 2017 Dec; 87():216-218. PubMed ID: 28993041
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related colitis and pancreatitis treated with infliximab.
    Ohwada S; Ishigami K; Yokoyama Y; Kazama T; Masaki Y; Takahashi M; Yoshii S; Yamano HO; Chiba H; Nakase H
    Clin J Gastroenterol; 2023 Feb; 16(1):73-80. PubMed ID: 36414888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
    Holmstroem RB; Nielsen OH; Jacobsen S; Riis LB; Theile S; Bjerrum JT; Vilmann P; Johansen JS; Boisen MK; Eefsen RHL; Marie Svane I; Nielsen DL; Chen IM
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab dose escalation triggered immune checkpoint inhibitor-induced colitis after 147 weeks of prolonged stable use in a patient with lung cancer: a case report.
    Soma K; Nishida T; Osugi N; Morimura O; Adachi S; Fujii Y; Sugimoto A; Mukai K; Nakamatsu D; Matsumoto K; Yamamoto M
    Clin J Gastroenterol; 2022 Feb; 15(1):128-133. PubMed ID: 34716545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
    Gambichler T; Doerler M; Scheel CH
    Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.
    Yasuda Y; Urata Y; Tohnai R; Ito S; Kawa Y; Kono Y; Hattori Y; Tsuda M; Sakuma T; Negoro S; Satouchi M
    Intern Med; 2018 May; 57(9):1269-1272. PubMed ID: 29279482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
    Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
    Front Immunol; 2021; 12():788499. PubMed ID: 34956219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
    Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.
    Kurozumi A; Takahashi H; Watanabe T; Iwasaki Y
    Thorac Cancer; 2021 May; 12(10):1625-1628. PubMed ID: 33783978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis.
    Alexander JL; Ibraheim H; Richards C; Shum B; Pavlidis P; Hunter N; Teare JP; Wotherspoon A; Furness A; Turajlic S; Pickering L; Larkin J; Speight A; Papa S; Powell N
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of severe colitis induced by the administration of pembrolizumab for pulmonary adenocarcinoma in a patient with ulcerative colitis].
    Nishimoto N; Sakakibara Y; Ishida H; Ishihara A; Tanaka S; Hasegawa H; Yamamoto S; Nakazuru S; Mori K; Mita E
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(12):1122-1129. PubMed ID: 34897141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier.
    Rasheed N; Anand R; Maddox M; Reyes C
    BMJ Case Rep; 2023 Sep; 16(9):. PubMed ID: 37751983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
    Bishu S; Melia J; Sharfman W; Lao CD; Fecher LA; Higgins PDR
    Gastroenterology; 2021 Feb; 160(3):932-934.e3. PubMed ID: 33096100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.